Knee Osteoarthritis Clinical Trial
— ArtzOfficial title:
A Multi-center, Randomized, Open-label, Parallel-arm Controlled Study Comparing Demand-based Monotherapy of Non-steroidal Anti-inflammatory Drug (NSAID) vs. Demand-based NSAID Combined With Sodium Hyaluronate Injection in the Treatment of Chinese Patients With Mild to Moderate Knee Osteoarthritis
This is a multi-center, randomized, open-label, parallel-arm phase IV clinical study, for
which a total of 300 patients with mild to moderate knee osteoarthritis will be enrolled. In
the first 4 weeks (run-in period), the subjects will receive on-demand treatment with
Diclofenac Sodium Sustained Release Tablets (DICL-SR) 75mg, quaque die(QD). After the run-in
period, the subjects, if their knee pain has not worsened to a level requiring surgical
treatment, will be randomized to two groups in 1:1 ratio: one group receiving Artz® via
intra-articular injection (once weekly, for 5 consecutive weeks) in combination with DICL-SR
75mg,quaque die(QD), for 12 consecutive weeks on demand. The other group receiving DICL-SR
75mg alone,quaque die(QD), for 12 consecutive weeks on demand. DICL-SR 75mg quaque die(QD)
may be administered to the subjects of both groups on demand as long as they have a knee
pain. If the knee pain has disappeared, this drug may be withdrawn. However, if the pain
occurs again and requires treatment, oral administration of DICL-SR may be resumed. A
subject is allowed to withdraw from this study prematurely if unable to tolerate the adverse
effects.
A total of 8 visits have been scheduled for this study, including Visit 1/screening period
(Week -4), Visit 2/baseline (Week 0), Visit 3 (Week 1), Visit 4 (Week 2), Visit 5 (Week 3),
Visit 6 (Week 4), Visit 7 (Week 8) and Visit 8 (Week 12).
A total of 300 subjects will participate in this study at 6 to 8 centers in China, and
patient enrollment is expected to take up to 12 months.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 2017 |
Est. primary completion date | October 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Adult Chinese subjects, at age=18, either gender, diagnosed with osteoarthritis of the target knee and Kellgren-Lawrence (KL) classification Grade 1~3, as evidenced by X-ray examination in the last 3 months (mild to moderate narrowing of joint space and / or marked osteophytes of tibiofemoral joint space) 2. Persist pain of the target knee after exercise, weight loss and physical therapy; 3. A baseline WOMAC A1 score for the target knee rated at 40-90mm (moderate to severe walk-associated pain) on 100mm Visual analogue scale(VAS); Able to understand and sign the Informed Consent Form (ICF) that has already been approved by the Independent Ethics Committee (IEC) Note: the informed consent may also be given by the duly authorized representative of the subject. Exclusion Criteria: 1. A diagnosis of bilateral knee osteoarthritis; 2. Clinically significant (requiring surgery) valgus or varus deformity of the knee joint, ligamentous laxity or unstable meniscus; 3. Complicated by inflammation or any other disease /condition (e.g., rheumatic arthritis, metabolic bone disease, psoriasis, gout, pseudogout, chondrocalcinosis, etc.) that may affect the knee joint; 4. A history of septicemia, clinically considered sub-acute infection of the target knee joint; 5. A history of surgery on the target knee (in the last 6 months); 6. A history of asthma, urticaria or allergy after use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs); 7. Severe hepatic or renal disease or hepatic /renal failure; 8. Any unscheduled surgery on the lower limb; 9. Clinically significant lower venous or lymphatic obstruction; 10. Clinically significant obvious exudation or inflammation of the target knee; 11. Skin disorders or infection at the injection site; 12. Pregnant or lactating women; 13. Known allergy to guanylin and / or any active ingredient or excipient of hyaluronic acid-based injection / diclofenac sodium; 14. Treatment with any hyaluronic acid (HA) or its derivatives for the target knee within six months before this trial; 15. Intra-articular (IA) injection of steroids into the target knee within 3 months before this trial; 16. Presence of any contraindication to IA injection, e.g., patients who are receiving anti-coagulation therapy or clinically have potential coagulation disorders (e.g., hepatic disease); 17. Presence of any clinically significant disease (e.g., significant mental or nervous disorders, alcohol/drug abuse), unstable/poorly controlled diseases, or other factors, which may affect their evaluation or participation in this study in the investigator's judgment 18. Perioperative pain associated with coronary artery bypass surgery (CABG); 19. A history of gastrointestinal bleeding or perforation following use of NSAIDs; 20. Presence of active gastrointestinal ulcer /bleeding, or a past history of recurrent ulcer/bleeding; Chief complaint complicated by pain beyond the target knee, |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of Chongqing Medical University | Chongqing | Chongqing |
China | Nanfang Hospital | Guangzhou | Guangdong |
China | Nanjing Drum Tower Hospital | Nanjing | Jiangsu |
China | Peking Union Medical College Hospital | Peking | Beijing |
China | Shanghai 6th People's Hospital | Shanghai | Shanghai |
China | The Second Affiliated Hospital of Xi'an Jiaotong University | Xi'an | Shaanxi |
Lead Sponsor | Collaborator |
---|---|
Kunming Baker Norton Pharmaceutical Sales Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Incidence of all adverse events (AEs) and serious adverse events (SAEs) | up to 16 weeks | ||
Primary | Compare the average daily doses (unit: pills) of the NSAID from Week9 (W9) to W12 between two groups | From W9 to W12 (4 weeks) | ||
Secondary | Compare the average daily doses (unit: pills) of the NSAID from W5 to W8, and W5 to W12 between two groups | From W5 to W8 (4 weeks), and W5 to W12 (8 weeks) | ||
Secondary | Compare the changes in the average daily doses (unit: pills) of the NSAID at the 8th and 12th week from baseline between two groups. | At the 8th week from baseline (1 week), and at the 12th week from baseline (1 week) | ||
Secondary | Compare the percentage changes in the average daily doses (unit: pills) of the NSAID at the 8th and 12th week from baseline between two groups. | At the 8th week from baseline (1 week), and at the 12th week from baseline (1 week) | ||
Secondary | Compare the days of NSAID consumption from W5 to W8, W9 to W12, and W5 to W12 between two groups. | From W5 to W8 (4 weeks), W9 to W12 (4 weeks), and W5 to W12 (8 weeks) | ||
Secondary | Compare the changes in WOMAC A1 score (walk-associated pain), WOMAC A, B and C score and patient global assessment (PTGA) at the 4th, 8th and 12th week from baseline between two groups. | At the 4th week from baseline (1 week), at the 8th week from baseline (1 week), and at the 12th week from baseline (1 week) | ||
Secondary | Compare the changes in clinical observer global assessment (COGA), and scores for activities of daily living (ADL) at the 4th, 8th and 12th week from baseline between two groups. | At the 4th week from baseline (1 week), at the 8th week from baseline (1 week), and at the 12th week from baseline (1 week) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04651673 -
Prescribed Knee Brace Treatments for Osteoarthritis of the Knee (Knee OA)
|
||
Completed |
NCT05677399 -
Knee Osteoarthritis Treatment With Peloidotherapy and Aquatic Exercise.
|
N/A | |
Active, not recruiting |
NCT04043819 -
Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis
|
Phase 1 | |
Recruiting |
NCT06000410 -
A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
|
Phase 3 | |
Completed |
NCT05014542 -
Needling Techniques for Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT05892133 -
Prehabilitation Effect on Function and Patient Satisfaction Following Total Knee Arthroplasty
|
N/A | |
Recruiting |
NCT05528965 -
Parallel Versus Perpendicular Technique for Genicular Radiofrequency
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Active, not recruiting |
NCT02003976 -
A Randomized Trial Comparing High Tibial Osteotomy Plus Non-Surgical Treatment and Non-Surgical Treatment Alone
|
N/A | |
Active, not recruiting |
NCT04017533 -
Stability of Uncemented Medially Stabilized TKA
|
N/A | |
Completed |
NCT04779164 -
The Relation Between Abdominal Obesity, Type 2 Diabetes Mellitus and Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT04006314 -
Platelet Rich Plasma and Neural Prolotherapy Injections in Treating Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT05423587 -
Genicular Artery Embolisation for Knee Osteoarthritis II
|
N/A | |
Enrolling by invitation |
NCT04145401 -
Post Market Clinical Follow-Up Study- EVOLUTION® Revision CCK
|
||
Active, not recruiting |
NCT03781843 -
Effects of Genicular Nerve Block in Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT05974501 -
Pre vs Post Block in Total Knee Arthroplasty (TKA)
|
Phase 4 | |
Completed |
NCT05324163 -
Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis
|
Phase 3 | |
Completed |
NCT05529914 -
Effects of Myofascial Release and Neuromuscular Training for Pes Anserine Syndrome Associated With Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT05693493 -
Can Proprioceptive Knee Brace Improve Functional Outcome Following TKA?
|
N/A | |
Not yet recruiting |
NCT05510648 -
Evaluation of the Effect of High-intensity Laser Therapy in Knee Osteoarthritis
|
N/A |